Generic Name and Formulations:
Telavancin (as HCl) 750mg; per vial; pwd for IV infusion after reconstitution and dilution; preservative-free.
Indications for VIBATIV:
Complicated skin and skin structure infections due to susceptible gram (+) bacteria. Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) due to Staphylococcus aureus.
≥18yrs: Give by IV infusion over 60 mins. Complicated skin and skin structure: treat for 7–14 days. HABP/VABP: treat for 7–21 days. Normal renal function: 10mg/kg once every 24hrs. Renal impairment: CrCl 30–50mL/min: 7.5mg/kg every 24hrs; CrCl 10–<30mL/min: 10mg/kg every 48hrs; CrCl<10mL/min or dialysis: not recommended.
<18yrs: not studied.
Concomitant IV unfractionated heparin sodium.
Increased mortality in HABP/VABP patients with pre-existing moderate or severe renal impairment. Nephrotoxicity. Potential adverse developmental outcomes.
Increased mortality in patients with pre-existing moderate/severe renal impairment who were treated for HABP/VABP. Baseline CrCl≤50mL/min. Risk of nephrotoxicity; monitor renal function. Diabetes. CHF. Hypertension. Obtain (–) pregnancy test before treatment for women of childbearing potential; use appropriate effective contraception during treatment. Discontinue at first signs of hypersensitivity reaction. Known hypersensitivity to vancomycin. Congenital long QT syndrome, uncompensated heart failure, severe left ventricular hypertrophy: avoid. Pregnancy (Cat.C): not recommended, may cause fetal harm. Nursing mothers.
Caution with other drugs that can cause QT prolongation. Increased risk of renal toxicity with NSAIDs, ACE inhibitors, loop diuretics. May interfere with coagulation tests (eg, PT/INR, aPPT, activated clotting time, coagulation-based factor Xa tests) and some urine protein tests.
Dysgeusia, nausea, vomiting, foamy urine; nephrotoxicity (reevaluate if occurs), infusion reactions ("red man syndrome"), superinfection (eg, antibiotic-associated colitis), QT prolongation, C.difficile-associated diarrhea.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Prioritizing Rest in Hospital Settings: Poor Sleep Increases Costs, Complications, and Mortality
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- Addressing Commercial Incentives in the Medical Device Industry
- Cancer Patients Treated With Step III Opioids Often Have Sleep Disturbances
- Low Literacy Self-Management Program for Chronic Pain May Be Effective